United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - paracetamol - suppository - 250mg

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg;   - film coated tablet - 150 mg - active: ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white ys-22-18096 purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 250mg - coated tablet - 250 mg - active: metformin hydrochloride 250mg excipient: magnesium stearate opadry clear oy-29020 povidone water

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - quetiapine fumarate 172.683mg equivalent to 150 mg quetiapine - film coated tablet - 150 mg - active: quetiapine fumarate 172.683mg equivalent to 150 mg quetiapine excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry yellow 03b82924 povidone purified talc sodium starch glycolate - acute and chronic psychoses, including schizophrenia.

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 200 mg - nevirapine is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults and pediatric patients 15 days and older. [see clinical studies (14.1, 14.2)] limitations of use: based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine is not recommended to be initiated, unless the benefit outweighs the risk, in: nevirapine is contraindicated: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to nevirapine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the risk of overall major birth defects for nevirapine compared with the background rate for major birth defects of 2.7% in the u.s. reference population of the metropolitan atlanta congenital defects program (m

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - lapatinib ditosylate 405.0mg eqv lapatinib - tablet, film coated - 250.00mg - lapatinib ditosylate 405.0mg eqv lapatinib 250.00mg

Singapore - English - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. (uen 200411241w) - tapentadol hydrochloride 174.72 mg eqv tapentadol - tablet, film coated - 150 mg - tapentadol hydrochloride 174.72 mg eqv tapentadol 150 mg

United States - English - NLM (National Library of Medicine)

fridababy, llc - witch hazel (unii: 101i4j0u34) (witch hazel - unii:101i4j0u34) - astringent - helps relieve pain and swelling from hemorrhoids and childbirth. - temporary relief from: irritation burning discomfort - irritation - burning - discomfort astringent - helps relieve pain and swelling from hemorrhoids and childbirth. - temporary relief from: irritation burning discomfort - irritation - burning - discomfort

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin for injection, usp, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin for injection, usp should not be administered to patients with a history of known allergy to oxaliplatin for injection, usp or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin for injection may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin for injection in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the pati